Navigation Links
Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and Narcolepsy
Date:6/1/2009

NUVIGIL Launch Enhanced by Robust Patient Access Programs

FRAZER, Pa., June 1 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that NUVIGIL(R) (armodafinil) Tablets [C-IV], a longer-lasting formulation of modafinil, is now available. NUVIGIL is indicated to improve wakefulness throughout the day for the millions of patients who struggle with excessive sleepiness associated with treated obstructive sleep apnea, shift work sleep disorder, also known as shift work disorder, and narcolepsy. Cephalon has finalized the commercialization plans for NUVIGIL and, beginning today, any patient with a NUVIGIL prescription should be able to obtain the medication from their pharmacy or have it filled within 24 hours.

"We are proud to be able to bring NUVIGIL to physicians and patients and to increase access to the medication through our patient support programs. Physicians have told us that they want and need a longer-lasting medication for their patients, and NUVIGIL delivers on that need," said Frank Baldino, Jr., Ph.D., Chairman and CEO, Cephalon.

For a multimedia version of this press release with video and downloadable images, please go to: http://mnr.onthescene.com/cephalon/NUVIGIL.html.

Expanded Access Programs

As part of the launch of NUVIGIL, Cephalon is introducing several new programs designed to expand access for both patients and healthcare providers. To assist insured patients with co-pay costs for NUVIGIL, Cephalon will offer the NUVIGIL Prescription Savings Program. Through this program, eligible patients will receive a co-pay savings at the pharmacy to reduce their out-of-pocket costs to fill the prescription. To help patients and healthcare providers navigate the autho
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes
2. Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
3. Cephalon Acquires Controlling Interest in Arana Therapeutics
4. Cephalon Quarterly Conference Call Invitation
5. Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
6. Cephalon Quarterly Conference Call Invitation
7. Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference
8. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
9. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
10. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... July 10, 2014 For the first time, researchers ... Aboriginal population in Canada uses health care. A new ... to clearly demonstrate the unique challenges faced by urban ... St. Michael,s Hospital. , The findings, published today ... urban First Nations individuals and the general population. , ...
(Date:7/9/2014)... was told she had an aneurysm, she figured an invasive ... "I was devastated," said Wakulich, who is 56 years old ... a serious diagnosis. Then I met Dr. Bernard Bendok who ... invasive procedure. It was something I didn,t even know was ... U.S. clinical trial to evaluate the safety and effectiveness of ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
(Date:7/9/2014)... found that fecal transplantation is effective and safe for ... is the result of a study led by Colleen ... Gastrointestinal Medicine at The Women,s Medicine Collaborative. The study ... of print in the American Journal of Gastroenterology ... diff , has increased to epidemic proportions over the ...
(Date:7/9/2014)... are personal and subjective, the human brain turns ... emotions across different senses, situations and even people, ... Adam Anderson. , "We discovered that fine-grained patterns ... area of the brain associated with emotional processing, ... individual,s subjective feeling," says Anderson, associate professor of ...
Breaking Medicine News(10 mins):Health News:Urban Aboriginal people face unique health challenges 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2
... bleary- eyed Britons, relief from hay fever may soon ... designed to prevent// allergic reactions like a running nose, itching eyes, ... vaccine pill contains small amounts of Timothy grass pollen; main allergens ... before hay fever season. ,This pill follows the hay ...
... at Cornell University in Ithaca and Weill Cornell Medical ... of 23 protein biomarkers// in cerebrospinal fluid that acts ... to identify patients living with Alzheimer’s disease. ... of the journal Annals of Neurology. ,Right ...
... for under-14 is being conducted at the Auckland Aquatic Center ... participating in a game at the West Wave Aquatic Centre ... problems and had to be admitted in the hospital. ... The council is deeply concerned by what had occurred and ...
... by the Canadian Food Inspection Agency to the public asking them ... fear that it may be contaminated with salmonella. ,This ... 0 33383 65201 6 and Dec. 7. as the best before ... shops but the agency fears some people may still have it ...
... zonal hospital found themselves in peril after doctors and ... The resignation en masse was submitted on Sunday, citing ... doctors – said senior physician Dr Gaurang Mishra. ... Dr. Raj Kumar Mahoto were beaten up by the ...
... For smokers, it ‘s bad news again. The Queensland (Australia) ... ,Smoking will soon be prohibited in cars carrying ... finding that one child under five years of age, dies ... ,The Queensland Health Minister while unveiling the Health of Queenslanders ...
Cached Medicine News:Health News:Revolutionary Pill Promises Relief for Hay Fever Sufferers 2Health News:Protein ‘Fingerprint’ in Spinal Fluid Could Spot Alzheimer’s Dise 2Health News:Protein ‘Fingerprint’ in Spinal Fluid Could Spot Alzheimer’s Dise 3
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , one of the nation,s largest institutional pharmacy ... as its new senior vice president of sales ... position, Gauff will be responsible for leading a ... Remedi,s innovative offerings, including the continued roll-out of ...
... CareFusion today launched the Nicolet™ EEG (Electroencephalography) ... wave data used for the diagnosis and treatment ... http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) The Nicolet EEG ... into a single, portable unit for pediatrics and adults ...
Cached Medicine Technology:Remedi SeniorCare® Appoints Corey Gauff SVP of Sales and Account Management 2CareFusion Launches Wireless Diagnostic and Monitoring Neurological Device 2
... The Sysmex pocH-100i is the first Sysmex ... low daily testing requirements. With its small ... differential from just 15 L of whole ... any small healthcare site including the emergency ...
... a self-contained, compact, easy-to-use, bedside automated cell ... Ichor system provides a hematology profile of ... platelet aggregation within five minutes. The test ... is added to both an EDTA baseline ...
... pacemaker family, which includes the world's ... the most advanced pacemaker technology available, ... the first and only U.S. commercially ... fibrillation (AF). The AF Suppression algorithm ...
... catheters that are controlled by an ... console processes the refrigerant, which when ... the catheter, creates cryogenic temperatures., ,The ... touch-screen interface. From this interface, the ...
Medicine Products: